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Abstract
Background: We previously found that cyclooxygenase 2 (COX-2) was expressed in dying oligodendrocytes at the 
onset of demyelination in the Theiler's murine encephalomyelitis virus-induced demyelinating disease (TMEV-IDD) 
model of multiple sclerosis (MS) (Carlson et al. J.Neuroimmunology 2006, 149:40). This suggests that COX-2 may 
contribute to death of oligodendrocytes.
Objective: The goal of this study was to examine whether COX-2 contributes to excitotoxic death of oligodendrocytes 
and potentially contributes to demyelination.
Methods: The potential link between COX-2 and oligodendrocyte death was approached using histopathology of MS 
lesions to examine whether COX-2 was expressed in dying oligodendrocytes. COX-2 inhibitors were examined for their 
ability to limit demyelination in the TMEV-IDD model of MS and to limit excitotoxic death of oligodendrocytes in vitro. 
Genetic manipulation of COX-2 expression was used to determine whether COX-2 contributes to excitotoxic death of 
oligodendrocytes. A transgenic mouse line was generated that overexpressed COX-2 in oligodendrocytes. 
Oligodendrocyte cultures derived from these transgenic mice were used to examine whether increased expression of 
COX-2 enhanced the vulnerability of oligodendrocytes to excitotoxic death. Oligodendrocytes derived from COX-2 
knockout mice were evaluated to determine if decreased COX-2 expression promotes a greater resistance to 
excitotoxic death.
Results: COX-2 was expressed in dying oligodendrocytes in MS lesions. COX-2 inhibitors limited demyelination in the 
TMEV-IDD model of MS and protected oligodendrocytes against excitotoxic death in vitro. COX-2 expression was 
increased in wild-type oligodendrocytes following treatment with Kainic acid (KA). Overexpression of COX-2 in 
oligodendrocytes increased the sensitivity of oligodendrocytes to KA-induced excitotoxic death eight-fold compared 
to wild-type. Conversely, oligodendrocytes prepared from COX-2 knockout mice showed a significant decrease in 
sensitivity to KA induced death.
Conclusions: COX-2 expression was associated with dying oligodendrocytes in MS lesions and appeared to increase 
excitotoxic death of oligodendrocytes in culture. An understanding of how COX-2 expression influences 
oligodendrocyte death leading to demyelination may have important ramifications for future treatments for MS.
Background
Multiple sclerosis (MS) is an inflammatory demyelinating
disease of the central nervous system (CNS) that fre-
quently occurs in young adults. Loss of oligodendrocytes
t h a t  m a i n t a i n  t h e  m y e l i n  s h e a t h  a s  w e l l  a s  d a m a g e  t o
axons and loss of neurons is observed with MS [1-3]. The
pathogenesis of MS is mediated through autoimmune
and inflammatory mechanisms [reviewed in [3,4]].
Potential mechanisms have been studied using the animal
models of MS, experimental autoimmune encephalomy-
elitis (EAE) [5] and Theiler's murine encephalomyelitis
virus-induced demyelinating disease (TMEV-IDD) [5,6].
Antagonists of glutamate receptors (GluR) of the α-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
(AMPA) class of GluRs have been shown to limit the
severity of disease in EAE [7-9], thus indicating how glu-
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tamate-mediated excitotoxicity could contribute to
demyelination.
Glutamate is well known to contribute to injury to
axons and death of neurons. However, glutamate medi-
ated excitotoxicity is not restricted to neurons. Oligoden-
drocytes express GluRs [10] and are susceptible to
excitotoxic death [11]. As such, oligodendrocyte excito-
toxic death and demyelination in MS may share similar
pathways known to contribute to neuronal excitotoxicity
associated with other neurological diseases. We postu-
lated that an important link between neuroinflammation
and glutamate-mediated excitotoxicity in demyelinating
disease could be mediated through the inducible isoform
of the enzyme cyclooxygenase (COX) called COX-2. In
our model, COX-2 expression in oligodendrocytes could
render these cells more susceptible to glutamate-medi-
ated excitotoxicity.
COX catalyzes the rate-limiting step in the generation
of prostanoids from arachidonic acid. A constitutive form
designated COX-1 and an inducible form, COX-2 have
been identified [12]. COX-2 expression is induced in neu-
rons of the CNS by glutamate receptor agonists [13,14].
COX inhibitors termed non-steroidal anti inflammatory
drugs (NSAIDs) directed against COX-2 are neuropro-
tective  in vitro [13,14] and in vivo [15,16] following
induction of excitotoxicity. Changes in COX-2 expression
by genetic manipulation can alter neuronal susceptibility
to excitotoxicity. Overexpression of neuronal COX-2 ren-
ders neurons more susceptible to excitotoxicity [17] and
neuronal loss in aged mice [18]. Conversely, loss of COX-
2 in knockout mice decreases neuronal death following
excitotoxic challenge [19]. This evidence illustrates how
COX-2 expression and activity can contribute to neu-
ronal excitotoxic cell death. If an analogous role for COX-
2 were present in excitotoxicity of oligodendrocytes, we
would predict that expression of COX-2 in oligodendro-
cytes may contribute to excitotoxic death of these cells.
We have shown that in MS lesions, COX-2 was expressed
by inflammatory cells [20] and oligodendrocytes [21].
Recently, we have demonstrated that COX-2 was
expressed in dying oligodendrocytes at the onset of
demyelination in TMEV-IDD [21]. This is consistent with
a role for COX-2 in death of oligodendrocytes and demy-
elination. In this context, we hypothesized that increased
COX-2 expression in oligodendrocytes could accentuate
glutamate-mediated excitotoxic death in oligodendro-
cytes and that decreased COX-2 expression (or inhibition
of enzymatic activity) may limit excitotoxicity and demy-
elination. In this study we examined the potential link
between COX-2 expression in oligodendrocytes and
death of oligodendrocytes in MS lesions. The potential
effects of COX-2 inhibitors were examined in the TMEV-
IDD model of MS along with the direct effects on
decreasing excitotoxic death of oligodendrocytes in cul-
ture. Finally, we addressed whether changes in oligoden-
drocyte expression of COX-2 by genetic manipulation
can alter sensitivity of oligodendrocytes to excitotoxic
death.
Methods
Materials
Tissue culture media and chemistry along with the Kainic
acid were purchased from Sigma Chemical Company
(Saint Louis, MO). Fetal bovine serum and horse serum
was purchased from Hyclone (Logan, UT). All the COX-2
inhibitors (CAY 10452, NS398 and CAY 10404) were pur-
chased from Cayman Chemical Company (Ann Arbor,
MI).
MS spinal cord plaque
T i s s u e  f o r  t h i s  s t u d y  w a s  o b t a i n e d  a t  a u t o p s y  f r o m  a
patient with clinical definite MS (CDMS) by McDonald
criteria and Poser criteria [1,2] confirmed by MRI of
brain and cervical spinal cord as well as presence of cere-
bral spinal fluid oligoclonal bands. Multiple cervical cord
lesions consistent with demyelinating lesions were
observed on MRI at the time of diagnosis. The patient
had an initial aggressive course of relapsing and remitting
disease followed by progressive decline. After a short
course of prednisone the patient did not pursue immuno-
therapy. The patient expired six years later and the cervi-
cal cord was resected with an autolysis time of 5 hours.
The tissue was fixed in paraformaldehyde. Studies of this
autopsy specimen were approved as exempt by the Uni-
versity of Utah IRB in accordance with DHHS federal reg-
ulation 45CFR46 [20,22].
TMEV-IDD model
All aspects of animal handling and care were conducted
with local Institutional Animal Care and Use Committee
(IACUC) approval in an Association for Assessment and
Accreditation of Laboratory Animal Care (AAALAC)-
a p p r o v e d  f a c i l i t y  ( T h e  V e t e r a n s  A f f a i r s  S a l t  L a k e  C i t y
Health Care System Veterinary Medical Unit). For each
time point, six mice were inoculated by IC (intracerebral)
injection with 2 × 105 plaque forming units (PFU) of the
DA strain of TMEV. At selected times the animals were
anesthetized and then perfused with phosphaste buffered
saline (PBS) containing 2% paraformaldehyde. Multiple
transverse sections were made through the spinal cord at
the cervical, thoracic, and lumbar levels. Scoring utilized
in our studies is as follows: spinal cord, midbrain, cerebel-
lum and cerebrum were evaluated in each animal and
scored for inflammation [5,6]. The scale for inflammation
is: 0 = no inflammatory cells; 1 = a few inflammatory cells
in the meninges; 2 = mild meningeal inflammatory cells
around blood vessels; 3 = moderate perivascular cuffing
with extension into the adjacent parenchymal space; andCarlson et al. Journal of Neuroinflammation 2010, 7:25
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4 = extensive perivascular cuffing and increased paren-
chymal inflammation. The scale for demyelination is: 0 =
none; 1 = subpial demyelination (subarachnoid inflam-
mation with just meningitis) (<10% demyelination); 2 =
extension beyond the subpial region (10-25% demyelina-
tion); 3 = large regions of white matter involvement (25-
50% demyelination); and 4 = extensive white matter
involvement in virtually the entire quadrant (>50% dem-
ylination). For statistical purposes multiple sections of
the CNS were obtained. For example, 10 sections of the
spinal cord were obtained and each quadrant of the cord
section was scored providing 40 data points/mouse. Data
from each group was analyzed using InStat3, a statistical
software package (graph pad Prism, San Diego CA).
Kruskal-Wallis Test (Nonparametric ANOVA) was used
for comparisons between groups.
Immunofluorescent confocal microscopy
Immunoreactivity was assessed with primary antibodies
to mouse antigens that included anti-COX-2, (Cayman
Chemicals, Ann Arbor, MI), anti-activated caspase 3 (Cell
Signaling Technology, Beverly, MA) and anti-CNPase
(Sigma, St. Louis, MO). Primary antibodies for human
MS lesions were goat anti COX-2 (Abcam, Cambridge,
MA), mouse anti-2',3'-cyclic-nucleotide 3'-phosphodi-
esterase (CNPase) (Sigma) and rabbit anti-activated cas-
pase 3 (Sigma). Primary antibodies were used at dilutions
established by our previous studies. Secondary fluoro-
chrome antibodies for mouse were donkey FITC conju-
gated anti-rabbit and Cy5 conjugated anti-mouse/rat
(Jackson immunoresearch laboratories, West Grove, PA)
and for human tissue were donkey FITC anti-goat, Cy5
anti-mouse and C3 anti-rabbit. Secondary antibodies
were used at concentrations from our previous estab-
lished results. The combined primary antibodies were
added and incubated overnight in a humidified chamber
at 4°C. Conjugated secondary antibodies were added for 1
hour at room temperature (RT). Negative protocol con-
trols were 20 μg/ml normal mouse/rat serum and 30 μg/
ml normal rabbit serum. Coverslips were mounted using
ProLong Gold anti-fade mounting media (Molecular
Probes Inc., Eugene, OR). Personal Confocal Microscopy
PCM-2000 (NIKON, Melville, NY) utilizes Argon, green
and red HeNe lasers to acquire images from the three dif-
ferent fluorochromes. Simple Personal Confocal Image
program (PCI, Compix, Cranberry Township, and PA)
was used to acquire digital images. The fluorochromes
were resolved from three different image channels. The
FITC label was detected with the Argon laser at 488 nm,
Cy5 with the red Argon laser at 633 nm and Cy3 was visu-
alized with the green HeNe laser at 563 nm. Tissues were
individually scanned with each respective laser filter.
Most images were acquired using the multi-focal pro-
gram (z-focus) to create a stereopsis image. The three dif-
ferent images were merged together to acquire the final
triple-colored image. propidium iodide (PI) image con-
verted to blue color during merge.
Dispersed oligodendrocyte cultures and excitotoxicity 
assay
Dispersed oligodendrocyte cultures were prepared from
P1 mouse pups essentially as described [23]. Oligoden-
drocytes were plated in 96 well plates and photographed
using phase contrast microscopy prior to treatment with
kainic acid. The same fields were photographed 24 hours
after KA treatment. For toxicity experiments, oligoden-
drocytes were identified by staining with olig-1 and
scored as dead by staining with PI. The percent survival
was calculated by dividing the number of live (cells not
stained with PI) observed after KA treatment divided by
the number of cells present prior to KA treatment. Three
or more fields were captured for each treatment group.
This assay is similar to our previous published assays to
determine neuronal survival following excitotoxicity
[14,24,25]. The percent survival was calculated as percent
control relative to the survival observed with no KA
treatment. Background death was typically less than 25%.
Organotypic spinal cord (slice) cultures
Organotypic spinal cord slice cultures were prepared as
previously described [26]. Spinal cords were rapidly
removed from P10 mouse pups after the animals were
sacrificed. Lumbar spinal cords were collected under
sterile conditions and sectioned transversely into 350 μm
thick sections using a McIlwain tissue chopper (Mickle
Lab Engineering, Gomshall, Surrey U.K.). The slices were
transferred in Hank Buffered Salt Solution (HBSS) (Invit-
rogen) and placed on the surface of a 30 mm diameter
Millipore Millicell-CM porous (0.04 μm) membranes
with 4-5 slices/membrane. The membranes were placed
in 6-well plates in 1 ml of minimal essential media
(MEM) with 25% horse serum, glutamine (2 mM) and 10
mM HEPES buffer (pH 7.4). Cultures were incubated at
37°C in a 5% CO2/95% humidified environment. Explants
were maintained in culture for 2 days before use in exper-
iments. Relative toxicity was calculated as the number of
dead cells per area in the white matter and gray matter
zones. The number of dead cells stained with activated
caspase 3 in the white matter zone was assessed 20-24
hours after the addition of KA.
Statistical analysis
Data was analyzed using InStat3, a statistical software
package (graph pad Prism, San Diego CA). Assessment of
significance of cell death between groups was done using
ANOVA Tukey-Kramer multiple comparisons test. All
comparisons satisfied the Kolmogorov and Smirnov
assumption test for Gaussian distributions thus allowing
parametric analyses.Carlson et al. Journal of Neuroinflammation 2010, 7:25
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Transgenic mice
The DNA construct used to generate the transgenic mice
designed to over-express COX-2 in oligodendrocytes
contained a 3.9 kb promoter region from the CNPase
promoter that contains the CNP1 and CNP2 promoters
[ 2 7 ]  i n  a  p B S / S K  v e c t o r  ( p r o v i d e d  b y  M i c h e l  G r a v e l
McGill University). An intermediate construct was gen-
erated with a 700 bp fragment cut with XhoI containing
the poly A sequence and was ligated downstream from
the CNP promoters following linearization with XhoI.
The resulting vector was subsequently cut with HindIII
and BamHI (in sites between the poly A region and the
CNP promoters) and a 2 kb fragment (HindIII/BclI) con-
taining the human COX-2 gene (hCOX-2) (provided by
Steve Prescott, University of Oklahoma) was ligated into
the vector. The desired clone containing the CNP pro-
moters upstream of the hCOX-2 gene followed by a poly
A sequence was confirmed by DNA sequence analyses
(University of Utah sequencing core laboratory). A 6.6 Kb
fragment from this clone containing the promoter
regions, hCOX-2 gene and poly A region was generated
following digestion with XhoI/XbaI and was purified and
subsequently injected into embryos to generate the trans-
genic mice (performed at the University of Utah trans-
genic core laboratory). Positive clones were screened
using PCR primer pairs specific to the hCOX-2 gene
(Primer pairs: forward primer = 5'-TGT GCT TAA ACA
GGA GCA TCC, reverse primer = 5'-TTG AAG TGA
TAG CCA CTC AAG, yielding a 132 bp PCR product).
COX-2 knockout mice were purchased from Taconic
F a r m s  ( G e r m a n t o w n ,  N Y ) .  P o s t - n a t a l  p u p s  u s e d  a s  a
source of oligodendrocytes for cultures were generated
from a cross with a homozygous knockout (COX-2 -/-)
male and a heterozygous knockout female (COX-2 +/-).
The mouse pups were screened with the primer sets out-
lined [28]. The sequences of the primers are: wild type
forward = 5'-ACA CCT TCA ACA TTG AAG ACC, KO
target forward = 5'-ACG CGT CAC CTT AAT ATG CG,
COX-2 reverse = 5'-ATC CCT TCA CTA AAT GCC
CTC. PCRs with all three primers generate products of
about 700 bp for wild-type and 875 bp for the knock-out.
Results
COX-2 expression in dying oligodendrocytes in an MS 
lesion
We have shown previously that COX-2 is expressed in
dying oligodendrocytes at the onset of demyelination in
the TMEV-IDD model of MS [21]. In order to assess
whether COX-2 might also be associated with dying oli-
godendrocytes in MS lesions, we stained MS lesions with
an oligodendrocyte marker (CNPase) along with a
marker for cell death (activated caspase 3) and asked
whether COX-2 was associated with these markers. As
seen in Figure 1, COX-2 was extensively associated with
oligodendrocytes that contained activated caspase 3. This
indicates that like the lesions in the TMEV-IDD model,
dying oligodendrocytes in MS lesions can also express
COX-2.
The effect of COX-2 inhibitors on demyelination in TMEV-
IDD
If the COX-2 expressed in oligodendrocytes in the
TMEV-IDD model of MS contributes to cell death then
inhibitors of this enzyme would be predicted to contrib-
ute to cell viability. In order to test this possibility, the
effect of COX-2 inhibitors on demyelination was exam-
ined in the TMEV-IDD model. As seen in Figure 2, there
was a significant reduction in demyelination when COX-
2 inhibitors were administered two weeks after infection
with TMEV. Interestingly, there was no effect of COX-2
inhibitors on the parameters of inflammation (see meth-
ods). These results are consistent with COX-2 contribut-
ing to oligodendrocyte death leading to demyelination.
Inhibition of COX-2 protects white matter excitotoxic death 
in spinal cord slice cultures
The previous findings are consistent with a role for COX-
2 contributing to the loss of oligodendrocytes in demyeli-
nating lesions. One way in which oligodendrocytes can be
lost in demyelinating disease is through GluR-mediated
excitotoxic death. Oligodendrocytes express GluRs [10]
and are susceptible to excitotoxic death [11]. Further,
inhibitors of GluRs can decrease demyelination in the
EAE model of MS [7-9]. In order to test whether COX-2
inhibitors could protect white matter oligodendrocytes
against excitotoxic death, an in vitro spinal cord slice cul-
ture system was used. This system retains neuro-anatom-
ical relationships and allows the examination of
compounds such as COX-2 inhibitors that could protect
against excitotoxic death [26]. As seen in Figure 3, the
GluR agonist Kainic Acid (KA) produces a robust induc-
tion of white matter cell death as indicated by the appear-
ance of marker for cell death activated caspase 3. This
marker for cell death has been observed in excitotoxic
death of oligodendrocytes [29]. However, addition of the
COX-2 inhibitor NS398 produced greater than a two-fold
reduction in the amount of activated caspase 3 in white
matter (Figure 4). COX-2 inhibitors also diminished a
similar amount of KA-induced gray matter excitotoxicity.
This result in gray matter is consistent with other reports
showing that inhibition of COX-2 protects against neu-
ronal excitotoxic death [13-17,26].
GluR-induced expression of COX-2 in purified dispersed 
oligodendrocyte cultures
The previous results are consistent with a role for COX-2
in oligodendrocyte death. However, the previous experi-
ments with spinal cord slice cultures do not distinguish
whether the protective effects of COX-2 inhibitors areCarlson et al. Journal of Neuroinflammation 2010, 7:25
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directed towards oligodendrocytes or mediated through
other cell types. In order to examine the direct effects on
oligodendrocytes we used a cell culture system with dis-
persed oligodendrocytes purified from post-natal mice
(see methods). This system has two unique advantages.
The first advantage is that the direct effects of COX-2
inhibitors on oligodendrocyte viability can be examined
independent of other cell types. Another advantage is
that these effects can also be examined for oligodendro-
cyte precursor cells in undifferentiated cultures. The lat-
ter is important to infer potential implications on
oligodendrocyte precursor cells that contribute to remy-
elination.
In neurons, activation of GluRs induces COX-2 expres-
sion [13,14] which can contribute to excitotoxic neuronal
death. In order to determine whether a similar effect of
GluR activation occurs for oligodendrocytes, dispersed
cultures were treated with sub lethal doses of KA and the
amount of COX-2 expression examined by immunofluo-
rescent confocal microscopy. As seen in Figure 5, cultures
treated with KA show a robust induction of COX-2 24
hours after KA treatment when compared to control cul-
tures. This is consistent with a potential role of COX-2 in
excitotoxic death of oligodendrocytes.
COX-2 inhibitors protect against excitotoxic death of 
oligodendrocytes in dispersed cultures
The potential protective effect of the COX-2 inhibitor
CAY 10404 was examined in dispersed oligodendrocytes
treated with KA. As seen in Figure 6, treatment with
COX-2 inhibitor resulted in a 1.5 fold increase in surviv-
ing KA-treated oligodendrocytes at 24 hours. This result
indicates that COX-2 expression in oligodendrocytes
increases excitotoxic death.
Increased expression of COX-2 in oligodendrocytes 
enhances excitotoxic death
The previous results with COX-2 inhibitors provide sup-
portive evidence for a role for COX-2 in excitotoxic death
Figure 1 Expression of COX-2 in dying oligodendrocytes in an MS lesion. An MS spinal cord lesion was examined by confocal immunofluores-
cence after probing with antibodies to the oligodendrocyte marker CNPase (red), COX-2 (green) and activated caspase 3 (blue). (A) A low power image 
(10×) of the plaque shows the area of demyelination (bar = 80 μm). Two regions (see arrows 1 and 2) indicate the areas shown in higher magnification 
(40×) for panels B-F (bar in B = 20 μm). (B). The three color image for the region shown by arrow 1 in panel A. Note the co-expression of COX-2, acti-
vated caspase 3 and CNPase as indicated by white. (C-E) Individual channels are shown COX-2 (C), activated caspase 3 (D) and CNPase (E). The three 
color merged image is shown in panel F. Two examples of labeling of all three antigens (appearing white) are indicated with arrows.
Figure 2 Therapeutic effect of the COX-2 inhibitor CAY 10452 in 
TMEV-IDD. The COX-2 inhibitor CAY10452 decreases demyelina-
tion. Spinal cord sections from control and CAY10452 (35 days after in-
fection with TMEV) were stained with H&E and LFB and scored for 
inflammation and demyelination as described in methods. Compari-
sons between control and CAY10452 groups were done using the 
Mann-Whitney nonparametric t-test and the p values indicated above 
the error bars (SEM).Carlson et al. Journal of Neuroinflammation 2010, 7:25
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of oligodendrocytes. However, one potential caveat to
these results is that COX-2 inhibitors may have off-target
activities [30] that may promote protective effects inde-
pendent of COX-2 inhibition. Therefore, we used genetic
manipulation to alter COX-2 expression in order to assess
whether changes in the expression have an effect on oli-
godendrocyte vulnerability to excitotoxic death. A trans-
genic mouse was generated that was designed to increase
expression of COX-2 specifically in oligodendrocytes.
This was achieved by linking the human COX-2 gene
downstream from the oligodendrocyte promoter for the
CNPase gene (see methods). The human COX-2 gene has
essentially the same catalytic properties as the endoge-
nous mouse COX-2 gene, but contains some distinct
amino acid sequences that make it uniquely detectable
with human COX-2 specific antibodies (see methods).
When oligodendrocytes were isolated from these trans-
genic mice and probed with an antibody for COX-2 (that
can detect both mouse and human COX-2), it was appar-
ent that the oligodendrocytes derived from the transgenic
mice exhibit a robust increase in COX-2 expression com-
pared to wild-type oligodendrocytes (Figure 7). In order
to test our hypothesis that COX-2 expression in oligoden-
drocytes increases sensitivity to excitotoxic death, these
COX-2 transgenic oligodendrocytes were compared to
wild-type oligodendrocytes for their susceptibilities to
KA induced excitotoxic death. As seen in Figure 8, the
KA concentration response curve for the transgenic
COX-2 oligodendrocytes was shifted to the left when
compared to that seen with wild-type oligodendrocytes,
indicating that the transgenic COX-2 oligodendrocytes
are more sensitive to KA-induced excitotoxic death.
Comparison of the concentrations of KA required to kill
50% of the cells indicates that the COX-2 transgenic oli-
godendrocytes are eight-fold more sensitive to KA com-
pared to wild-type.
Figure 3 Excitotoxicity in the spinal cord explant cultures. A) A spinal cord culture was stained for expression of the neuronal marker MAP-2 (Blue) 
and for the oligodendrocyte marker oligodendrocyte-specific protein (OSP) (Red). One hemisphere is boxed to show the regions from other slices 
which appear in panels B and C (bar = 400 μm). Hemispheres of a slice cultures stained for MAP-2,(Blue), OSP (Red) and activated caspase 3 (green) 
are shown for untreated (B) control and kainic acid (KA) (C). (Magnifications are 2× for A and 4× for B and C, bar = 80 μm for B, C and = 20 for D μm). 
(D). A higher magnification (60×) of the white matter region showing oligodendrocytes stained for CNPase (red) and activated caspase 3 (green) and 
co-labeling with both as yellow. Examples of oligodendrocytes containing activated caspase 3 are shown (see white arrows). An example of a cell 
labeled for activated caspase 3 which is not an oligodendrocyte (and likely a motor neuron) is shown with a gray arrow.
Figure 4 COX-2 inhibitor mediated decrease of KA-induced acti-
vated caspase 3 in white matter and gray matter. The appearance 
of cells stained with the marker for cell death (activated caspase-3) was 
assessed in four spinal cord sections for white matter (left) and gray 
matter (right) with treatments of vehicle (control), kainic acid (KA) or 
kainic acid with the COX-2 inhibitor NS398 (KA/NS398). Error bars are 
SEM and P values determined by ANOVA Tukey-Kramer. This is a repre-
sentative experiment which has been repeated in two other experi-
ments.
Figure 5 COX-2 is induced in oligodendrocytes by Kainic Acid 
(KA). Dispersed oligodendrocyte cultures were treated with either ve-
hicle (Control) or KA and examined 24 hours later by confocal immun-
ofluorescence. COX-2 expression (green) is seen in the cells labeled 
with the oligodendrocyte specific marker Olig-1 (red), co-labeling ap-
pears yellow (see arrow). Magnification bar = 20 μm.Carlson et al. Journal of Neuroinflammation 2010, 7:25
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Loss of COX-2 expression makes oligodendrocytes less 
susceptible to excitotoxicity
As noted earlier, a decrease in COX-2 activity after treat-
ment with COX-2 inhibitors resulted in increased sur-
vival following an excitotoxic challenge with KA (see
Figures 4 and 6). An alternative approach to decreasing
COX-2 activity is to use oligodendrocytes derived from
COX-2 knockout mice. As seen in Figure 9, oligodendro-
cytes derived form COX-2 knockout mice showed a sig-
nificant (nearly two-fold) increase in survival to KA-
induced excitotoxic death. Interestingly, the same degree
of resistance to excitotoxic death was observed for both
the homozygous COX-2 knockout oligodendrocytes
(COX-2 -/-) as with the heterozygous (COX-2 -/+) oligo-
dendrocytes. This result indicates that complete elimina-
tion of COX-2 activity is not required for maximal
protection of oligodendrocytes under these conditions
and that merely reducing the activity two-fold of COX-2
(by gene dosage) results in maximal protection against
excitotoxic death. This specific COX-2 inhibitor (CAY
10404) also did not produce a significant increase in sur-
vival of the COX-2 (-/-) oligodendrocytes, consistent with
the protective effect of this inhibitor mediated through its
ability to block COX-2 activity (Figure 9).
Discussion
In this study we demonstrated that COX-2 was expressed
in dying oligodendrocytes in MS plaques in the cervical
Figure 9 Sensitivity of oligodendrocytes from COX-2 knockout 
mice to excitotoxic death and protection with COX-2 inhibitors. 
(A) Oligodendrocytes from COX-2 knockout mice are more resistant to 
KA-induced excitotoxicity. Dispersed oligodendrocyte cultures were 
prepared from wild-type (WT), heterozygous COX-2 knockout (COX-2 
+/-) and homozygous COX-2 knockout (COX-2 -/-) and treated with KA. 
Surviving cells were scored 24 hours after KA treatment. This is the av-
erage of two independent experiments. (B) The COX-2 inhibitor CAY 
10404 does not protect COX-2 knockout oligodendrocytes from KA-in-
duced death. Dispersed oligodendrocyte cultures were prepared from 
COX-2 -/- mice and treated with KA in the presence or absence of CAY 
10404 (10 uM). Viability was assessed 24 hours after treatment with KA. 
There was no significant increase in the number of surviving oligoden-
drocytes in the CAY 10404-treated group. Error bars are SEM.
Figure 6 Protection of oligodendrocytes with the COX-2 inhibitor 
(CAY10404). Dispersed oligodendrocyte cultures were treated with 
KA in the presence or absence of CAY 10404 (10 uM) and analyzed 24 
hours later for cell death. Error bars are SEM.
Figure 7 Cultures of Oligodendrocytes derived from COX-2 trans-
genic mice over-express COX-2. Dispersed wild-type cultures were 
prepared from wild-type and transgenic mice the over-express COX-2 
specifically in oligodendrocytes (generated with the CNPase promoter 
fused to the human COX-2 gene. The oligodendrocyte marker to Olig-
1 appears red and COX-2 appears green. Co-expression of both ap-
pears yellow. Magnification bar = 40 μm.
Figure 8 Vulnerability of wild-type and Oligo-COX-2 transgenic 
oligodendrocytes to KA-induced excitotoxicity. Dispersed oligo-
dendrocytes were treated to varying concentrations of KA and exam-
ined for cell death 24 hours later. Oligodendrocytes derived from the 
transgenic animals were 8-fold more sensitive to KA than wild-type. 
Note, the x-axis is not a linear scale.Carlson et al. Journal of Neuroinflammation 2010, 7:25
http://www.jneuroinflammation.com/content/7/1/25
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spinal cord from an MS patient. This indicates that MS
lesions may share similar pathology as was seen in the
TMEV-IDD model of MS where we reported that COX-2
was also expressed in dying oligodendrocytes at the onset
of demyelination. These results infer that COX-2 may
play a role in oligodendrocyte death and demyelination.
We have extended these observations to show that COX-
2 inhibitors decrease the amount of demyelination in
TMEV-IDD. We have further demonstrated that COX-2
inhibitors protect oligodendrocytes in culture from exci-
totoxic death and that increased COX-2 expression
increases excitotoxic death of oligodendrocytes while
decreased COX-2 expression diminishes excitotoxic
death. Combined, these results strongly support a role for
COX-2 expression in oligodendrocytes as a contributing
component in excitotoxic death of oligodendrocytes and
a potential contributor to demyelinating disease. Our
results may also have important implications for a role of
COX-2 in remyelination as well. The purified oligoden-
drocytes in our dispersed cultures were composed of
greater than 90% oligodendrocyte precursor cells as indi-
cated by the presence of nuclear olig1 staining [31,32]
(data not shown). As such, COX-2 expression contributes
to loss of precursor cells and subsequently limits poten-
tial remyelination. In this context, COX-2 inhibitors may
contribute to oligodendrocyte precursor cell viability and
may help with remyelination in cases where precursor
cells may be limited.
These findings extend our earlier observations that
COX-2 is expressed in oligodendrocytes in MS lesions
and that COX-2 is expressed in dying oligodendrocytes at
the onset of demyelination in the TMEV-IDD model of
MS [21]. These findings suggest that COX-2 inhibitors
may have potential therapeutic application to MS. How-
ever, relatively little is known about how NSAIDs may
limit disease in MS. There are reports of clinical use of
NSAIDs for MS in management of side effects associated
with IFN therapies [33] and aspirin use for limiting the
severity of MS-related fatigue [34] and premenstrual
associated pseudoexacerbations [35]. However, these
studies were not designed to test the potential for limiting
demyelination in disease and there are no other reports of
therapeutic effects of NSAIDs for MS. In contrast to
these limited examples of NSAID use with MS disease,
COX inhibitors have been tested for their ability to limit
disease in animal models of MS.
Studies with COX-2 inhibitors in animal models of MS
also support a role for COX-2 as a contributor to disease
pathology. Two groups have reported that administration
of COX-2 inhibitors in EAE diminished the severity and
incidence of disease and decreased demyelination and
inflammation [36,37]. In both cases, the therapeutic
effects in EAE were only observed when the COX-2
inhibitors were initiated immediately after immunization
and maintained throughout the course of the study.
Miyamoto and colleagues [37] also observed an improve-
ment in EAE when the COX-2 inhibitor Celecoxib was
initiated at onset of clinical symptoms (40% improvement
in combined clinical score). Miyamoto et al., suggest that
the therapeutic effect of Celecoxib in the induction phase
of monophasic EAE is in part due to COX-2 independent
a c t i o n s  o f  t h i s  d r u g  [ 3 7 ] .  T h e y  f o u n d  t h a t  C e l e c o x i b -
induced improvements in EAE clinical scores were equiv-
alent in wild-type and COX-2 knockout mice [37].
Another COX-2 inhibitor nimesulid, showed no thera-
peutic effects in EAE in wild-type mice. However, their
results with nimesulid stand in contrast to investigations
by Muthian et al., which demonstrated therapeutic effects
with 4 different COX-2 inhibitors [36]. Other non-spe-
cific COX-2 inhibitors (indomethacin) have also been
shown to have therapeutic effects in EAE [38,39]. Other
enzymes involved in the generation of prostanoids have
been implicated in the pathology of EAE. EAE is less
severe in mice that lack the microsomal PGE synthase 1
(MPGES-1) gene that codes for the enzyme that synthe-
sizes PGE2 from COX-derived PGH2 [40]. This finding
suggests that PGE2 may be a major contributor to EAE.
Muthian et al., reported that the therapeutic effects of
COX-2 inhibitors in the induction phase of EAE were due
in part to immunomodulatory effects resulting from sup-
pression of T-cell signaling through interleukin-12 (IL-
12) [36]. In our studies of MS plaques, we showed that
COX-2 was expressed in inflammatory macrophages and
microglia in association with inducible nitric oxide syn-
thase (iNOS) in chronic active lesions [20]. COX-2 and
iNOS together, could interact to form the highly toxic
peroxynitrite species which was also associated with MS
plaques [41-43]. We postulated that the presence of
COX-2 and iNOS in MS plaques could also contribute to
the increases in local concentrations of glutamate which
could lead to axonal damage and cell death of oligoden-
drocytes and neurons [20]. We also detected COX-2 and
iNOS expression in a case of optic neuritis associated
with continuing sub-clinical demyelination while on
interferon therapy [22].
In the present investigation we have identified another
potential mechanism by which COX-2 inhibition could
impact demyelinating disease. COX-2 expression in oli-
godendrocytes appears to increase susceptibility to exci-
totoxicity in a fashion similar to that seen in neuronal
excitotoxic death [17,18]. As such, expression of COX-2
in oligodendrocytes and oligodendrocyte precursor cells
could have important consequences with respect to
degenerative and regenerative components of MS. There
may be similarities in mechanisms of excitotoxic death
between neurons and oligodendrocytes. Mechanisms
involving COX-2 in neuronal death have been estab-
lished; however, these mechanisms for excitotoxic oligo-Carlson et al. Journal of Neuroinflammation 2010, 7:25
http://www.jneuroinflammation.com/content/7/1/25
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dendrocyte death remain to be elucidated. In neurons,
the contribution of COX-2 to neuronal death is mediated
by specific COX-2 generated prostanoids. COX catalyzes
the initial reactions in the synthesis of prostanoids (PGs),
prostaglandin D2 (PGD2), prostaglandin E2 (PGE2),
prostaglandin F2α (PGF2α), prostacyclin (PGI2) and
thromboxane (TxA2) from arachidonic acid [12]. Each of
these PGs activates specific G-protein coupled receptors
that, depending on the prostanoid, vary in number from
one to four receptors as is seen for PGE2 (receptors EP1-
4) [see [44]]. These four receptors for PGE2 (EP1-4), have
distinct patterns of expression in different tissues and dif-
ferent pharmacological properties and each receptor is
coupled to distinct intracellular signaling pathways [38].
In neuronal excitotoxic death, COX-2 generated PGE2
has been shown to be the major prostanoid responsible
for the contribution of COX-2 to neuronal death in vitro
[14] and in vivo [45]. Three groups have since shown that
PGE2 stimulation of the EP1 prostanoid receptor is
responsible for the contribution of COX-2 to NMDA-
stimulated neuronal death in vivo [46,47] and in vitro
[[25,48], see [49] for review]. Iadecola and colleagues fur-
ther demonstrated that EP1 activation impaired the Na+ -
Ca2+  exchanger (NCX) which helps neurons remove
excess intracellular Ca2+  following NMDA stimulation
[46]. The resulting dysregulation of intracellular Ca2+ led
to overload of Ca2+ in neurons and subsequent death. EP1
receptor activation has also been linked to the AKT sig-
naling pathway that can contribute to neuronal death
[50]. However, PGE2 may have opposing effects on neu-
ronal viability depending on which receptor is activated.
Activation of EP1 contributes to neuronal excitotoxic
death, in contrast to activation of EP2 [51-53] and EP4
[50] which promote neuroprotection [see [49] for
review].
Much less is known about how specific prostanoids and
their receptors affect viability of oligodendrocytes, but
similar roles may be seen for oligodendrocyte death as are
seen with neurons. One study has linked specific pros-
tanoids to viability of oligodendrocytes. The prostanoid
PGD2 and its metabolite 15d-PGJ2 have been shown to
directly stimulate death of oligodendrocyte precursors in
vitro [54]. In this case, the effects of these prostanoids
were independent of prostanoid receptors and linked to
oxidative stress [54]. Other prostanoids (including PGE2)
were tested and had no direct toxic effects on oligoden-
drocytes [54]. However, it is important to note that with
neurons, PGE2 was necessary, but not sufficient to
induce excitotoxic death. In this case, the prostanoid was
not toxic by itself, but could contribute to the effect of the
excitotoxin. Further investigations will be required to
determine what role specific prostanoids and their recep-
tors play in the excitotoxic death of oligodendrocytes.
Our study implicates COX-2 as a potential contributor
to oligodendrocyte death and demyelination. However,
the use of COX-2 inhibitors for treating MS may be com-
plicated due to cardiovascular disease side effects associ-
ated with some COX-2 inhibitors [55,56]. An
understanding of how COX-2 contributes to oligoden-
drocyte viability may identify new targets for treatment
downstream of COX that may be safer and more effec-
tive.
Conclusion
This study demonstrates that COX-2 expression in oligo-
dendrocytes contributes to susceptibility to excitotoxic
death. These results suggest that inhibitors of COX-2
could limit oligodendrocyte excitotoxicity and demyeli-
nation and may be considered as potential therapies for
MS.
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